Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of IBI363 versus docetaxel in previously treated advanced squamous NSCLC
CTR20253956Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of IBI363 in Pulmonary squamous cell carcinoma, sponsored by InnoCare Pharma. Started Nov 2025; status: active.
02
Drugs
IBI363
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20253956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253956.